Literature DB >> 28069875

15α-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models.

Tyvette S Hilliard1, Gabriella Miklossy1, Christopher Chock2, Peibin Yue1, Philip Williams2, James Turkson3.   

Abstract

Studies with 15α-methoxypuupehenol (15α-MP), obtained from the extracts of Hyrtios species, identified putative targets that are associated with its antitumor effects against human glioblastoma and breast cancer. In the human glioblastoma (U251MG) or breast cancer (MDA-MB-231) cells, treatment with 15α-MP repressed pY705Stat3, pErk1/2, pS147CyclinB1, pY507Alk (anaplastic lymphoma kinase), and pY478ezrin levels and induced pS10merlin, without inhibiting pJAK2 (Janus kinase) or pAkt induction. 15α-MP treatment induced loss of viability of breast cancer (MDA-MB-231, MDA-MB-468) and glioblastoma (U251MG) lines and glioblastoma patient-derived xenograft cells (G22) that harbor aberrantly active Stat3, with only moderate or little effect on the human breast cancer, MCF7, colorectal adenocarcinoma Caco-2, normal human lung fibroblast, WI-38, or normal mouse embryonic fibroblast (MEF Stat3fl/fl) lines that do not harbor constitutively active Stat3 or the Stat3-null (Stat3-/-) mouse astrocytes. 15α-MP-treated U251MG cells have severely impaired F-actin organization and altered morphology, including the cells rounding up, and undergo apoptosis, compared with a moderate, reversible morphology change observed for similarly treated mouse astrocytes. Treatment further inhibited U251MG or MDA-MB-231 cell proliferation, anchorage-independent growth, colony formation, and migration in vitro while only moderately or weakly affecting MCF7 cells or normal mouse astrocytes. Oral gavage delivery of 15α-MP inhibited the growth of U251MG subcutaneous tumor xenografts in mice, associated with apoptosis in the treated tumor tissues. Results together suggest that the modulation of Stat3, CyclinB1, Alk, ezrin, merlin, and Erk1/2 functions contributes to the antitumor effects of 15α-MP against glioblastoma and breast cancer progression. Mol Cancer Ther; 16(4); 601-13. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28069875      PMCID: PMC5380601          DOI: 10.1158/1535-7163.MCT-16-0291

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

1.  Methanol adduct of puupehenone, a biologically active derivative from the marine sponge Hyrtios species.

Authors:  M L Bourguet-Kondracki; F Lacombe; M Guyot
Journal:  J Nat Prod       Date:  1999-09       Impact factor: 4.050

2.  Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Authors:  Xiaolei Zhang; Peibin Yue; Brent D G Page; Tianshu Li; Wei Zhao; Andrew T Namanja; David Paladino; Jihe Zhao; Yuan Chen; Patrick T Gunning; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

3.  Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein.

Authors:  Michel Bernier; Rajib K Paul; Alejandro Martin-Montalvo; Morten Scheibye-Knudsen; Shaoming Song; Hua-Jun He; Sean M Armour; Basil P Hubbard; Vilhelm A Bohr; Lili Wang; Yaping Zong; David A Sinclair; Rafael de Cabo
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

4.  Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.

Authors:  Peibin Yue; Francisco Lopez-Tapia; David Paladino; Yifei Li; Chih-Hong Chen; Andrew T Namanja; Tyvette Hilliard; Yuan Chen; Marcus A Tius; James Turkson
Journal:  Cancer Res       Date:  2015-06-18       Impact factor: 12.701

5.  Clinicopathological features and treatment strategy for triple-negative breast cancer.

Authors:  Yutaka Yamamoto; Hirotaka Iwase
Journal:  Int J Clin Oncol       Date:  2010-07-15       Impact factor: 3.402

6.  Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.

Authors:  Gabriella Miklossy; Ui Joung Youn; Peibin Yue; Mingming Zhang; Chih-Hong Chen; Tyvette S Hilliard; David Paladino; Yifei Li; Justin Choi; Jann N Sarkaria; Joel K Kawakami; Supakit Wongwiwatthananukit; Yuan Chen; Dianqing Sun; Leng Chee Chang; James Turkson
Journal:  J Med Chem       Date:  2015-09-17       Impact factor: 7.446

7.  Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells.

Authors:  Nadine A Binai; Annette Damert; Gert Carra; Stephan Steckelbroeck; Johannes Löwer; Roswitha Löwer; Silja Wessler
Journal:  Int J Cancer       Date:  2010-07-01       Impact factor: 7.396

8.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Authors:  Daoyan Wei; Xiangdong Le; Leizhen Zheng; Liwei Wang; Jennifer A Frey; Allen C Gao; Zhihai Peng; Suyun Huang; Henry Q Xiong; James L Abbruzzese; Keping Xie
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

9.  Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.

Authors:  Anne S Tsao; Dandan He; Babita Saigal; Suyu Liu; J Jack Lee; Srinivasa Bakkannagari; Nelson G Ordonez; Waun Ki Hong; Ignacio Wistuba; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

10.  A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.

Authors:  David Paladino; Peibin Yue; Hideki Furuya; Jared Acoba; Charles J Rosser; James Turkson
Journal:  Oncotarget       Date:  2016-02-09
View more
  5 in total

1.  Comparing Apoptosis and Necrosis Effects of Arctium Lappa Root Extract and Doxorubicin on MCF7 and MDA-MB-231 Cell Lines

Authors:  Fereshteh Ghafari; Mohammad Reza Rajabi; Tahereh Mazoochi; Mohsen Taghizadeh; Hossein Nikzad; Mohammad Ali Atlasi; Aliakbar Taherian
Journal:  Asian Pac J Cancer Prev       Date:  2017-03-01

2.  Benzimidazoisoquinoline derivatives inhibit glioblastoma cell proliferation through down-regulating Raf/MEK/ERK and PI3K/AKT pathways.

Authors:  Ya-Jun Zhang; Zhi-Gang Xu; Shi-Qiang Li; Liu-Jun He; Yan Tang; Zhong-Zhu Chen; Dong-Lin Yang
Journal:  Cancer Cell Int       Date:  2018-06-28       Impact factor: 5.722

3.  Cytotoxic effects of auraptene against a human malignant glioblastoma cell line.

Authors:  Amir R Afshari; Mostafa Karimi Roshan; Mohammad Soukhtanloo; Ahmad Ghorbani; Farzad Rahmani; Mohammad Jalili-Nik; Mohammad Mahdi Vahedi; Azar Hoseini; Hamid R Sadeghnia; Hamid Mollazadeh; Seyed Hadi Mousavi
Journal:  Avicenna J Phytomed       Date:  2019 Jul-Aug

4.  Pharmacologic Inhibition of Ezrin-Radixin-Moesin Phosphorylation is a Novel Therapeutic Strategy in Rhabdomyosarcoma.

Authors:  Austin Proudfit; Nabanita Bhunia; Debasis Pore; Yvonne Parker; Daniel Lindner; Neetu Gupta
Journal:  Sarcoma       Date:  2020-09-09

5.  Combination therapy of 7-O-succinyl macrolactin A tromethamine salt and temozolomide against experimental glioblastoma.

Authors:  Jun Jin; Kihwan Hwang; Jin-Deok Joo; Jung Ho Han; Chae-Yong Kim
Journal:  Oncotarget       Date:  2017-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.